Abstract
Approximately 2 million people in the United States suffer from severe dementia, and an additional 5 million have mild to moderate dementia. As life expectancy and the proportion of older individuals in the population continue to increase, dementia will become an ever more significant health problem, compounded by its effects on the families of those affected. If the course of dementia is not modified by treatment, the number of individuals who will be affected by degenerative dementia in the coming decades will increase dramatically [1,2].
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Schoenberg BS: Epidemiology of Alzheimer’s disease and other dementing illnesses. J Chronic Dis 1986, 39:1095–1104.
Hagnell O, Ojesjo L, Rorsman B: Incidence of dementia in the Lundby study. Neuroepidemiology 1992, 11:61–66.
The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization; 1992.
Hughes CP, Berg L, Danziger WL, et al.: A new clinical scale for the staging of dementia. Br J Psychiatry 1982, 140:566–572.
Petersen RC, Smith GE, Waring SC, et al.: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999, 56:303–308.
Marsden CD: Assessment of dementia. In Handbook of Clinical Neurology, vol 46. Edited by Frederiks JAM. Amsterdam: Elsevier Science Publishers; 1985:221–231.
Albert ML, Feldman RG, Willis AL: The’ subcortical dementia’ of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1974, 37:121–130.
Cummings JL, Benson DF: Subcortical dementia. Arch Neurol 1984, 41:874–879.
Larrabee GJ, McEntee WJ: Age-associated memory impairment: sorting out the controversies. Neurology 1995, 45:611–614.
Koivisto K, Reinikainen KJ, Hanninen MA, et al.: Prevalence of ageassociated memory impairment in a randomly selected population from eastern Finland. Neurology 1995, 45:741–747.
Kaye J, Quinn J: Clinical changes associated with normal aging. In Neurodegenerative Dementias. Edited by Clark CM, Trojanowski JQ. New York: McGraw-Hill; 2000.
Richards M, Stern Y, Mayeux R: Subtle extrapyramidal signs can predict the development of dementia in elderly individuals. Neurology 1993, 43:2184–2188.
Chui HC, Lyness SA, Sobel E, Schneider LS: Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer’s disease. Arch Neurol 1994, 51:676–681.
Petersen RC, Smith GE, Ivnik RJ, et al.: Apolipoprotein E status as a predictor of the development of Alzheimer’s disease in memory-impaired individuals. JAMA 1995, 273:1274–1278.
Daly E, Zaitchik D, Copeland M, et al.: Predicting conversion to Alzheimer disease using standardized clinical information. Arch Neurol 2000, 57:675–680.
Jack CR Jr, Petersen RC, Xu YC, et al.: Medial temporal atrophy on MRI in normal aging and very mild Alzheimer’s disease. Neurology 1997, 49:786–794.
Killiany RJ, Gomez-Isla T, Moss M, et al.: Use of structural magnetic resonance imaging to predict who will get Alzheimer’s disease. Ann Neurol 2000, 47:430–439.
Albert MS: Cognitive and neurobiologic markers of early Alzheimer disease. Proc Natl Acad Sci U S A 1996, 93:13547–13551.
Fox NC, Warrington EK, Seiffer AL, et al.: Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer’s disease: a longitudinal prospective study. Brain 1998, 121:1631–1639.
van Duijn CM: Epidemiology of the dementias: recent developments and new approaches. J Neurol Neurosurg Psychiatry 1996, 60:478–488.
Brayne C, Gill C, Huppert FA, et al.: Incidence of clinically diagnosed subtypes of dementia in an elderly population. Br J Psychiatr 1995, 167:255–262.
Perry E, McKeith I, Perry R, eds.: Dementia with Lewy Bodies: Clinical, Pathologic, and Treatment Issues. Cambridge: Cambridge University Press; 1996.
Weytingh MD, Bossuyt PMM, van Crevel H: Reversible dementia: more than 10% or less than 1%? A quantitative review. J Neurol 1995, 242:446–471.
Mahler ME, Cummings JL, Benson DF: Treatable dementias. West J Med 1987, 146:705–712.
Caine ED: Pseudodementia: current concepts and future directions. Arch Gen Psychiatry 1981, 38:1359–1364.
Nussbaum PD: Pseudodementia: a slow death. Neuropsychol Rev 1994, 4:71–90.
Abramowicz M: Drugs that cause psychiatric symptoms. Med Lett 1993, 30:65–70.
Sunderland T, Tariot PN, Cohen RM, et al.: Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. Arch Gen Psychiatry 1987, 44:418–426.
Blazer DG, Federspiel CF, Ray WA, Schaffner W: The risk of anticholinergic toxicity in the elderly: a study of prescribing practices in two populations. J Gerontol 1983, 38:31–35.
Cantu TG, Korek JS: Central nervous system reactions to histamine-2 receptor blockers. Ann Intern Med 1991, 114:1027–1034.
Tiraboschi P, Hansen LA, Alford M, et al.: Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000, 54:407–411.
Alexander EM, Wagner EH, Buchner DM, et al.: Do surgical brain lesions present as isolated dementia? A population-based study. J Am Geriatr Soc 1995, 43:138–143.
Clarfield AM: The reversible dementias: do they reverse? Ann Intern Med 1988, 109:476–486.
Adams RD, Fisher CM, Hakim S, et al.: Symptomatic occult hydrocephalus with “normal” cerebrospinal-fluid pressure. N Engl J Med 1965, 273:117–126.
Fisher CM: Hydrocephalus as a cause of disturbances of gait in the elderly. Neurology 1982, 32:1358–1363.
Wikkelso C, Andersson H, Blomstrand C, et al.: Normal pressure hydrocephalus: predictive value of the cerebrospinal fluid tap-test. Acta Neurol Scand 1986, 73:566–573.
Graff-Radford NR, Godersky JC, Jones MP: Variables predicting surgical outcome in symptomatic hydrocephalus in the elderly. Neurology 1989, 39:1601–1604.
Grabowski TJ, Damasio AR: The Neuropathology of Dementia, edn 2. Edited by Esiri MM, Lee VM-Y, Trojanowski JQ. New York: Cambridge University Press; 2004.
Benton AL: Neuropsychological assessment. Annu Rev Psychol 1994, 45:1–23.
Jones RD, Tranel D, Benton A, Paulsen J: Differentiating dementia from “pseudodementia” early in the clinical course: utility of neuropsychological tests. Neuropsychology 1992, 6:13–21.
Harner RN: EEG evaluation of the patient with dementia. In Psychiatric Aspects of Neurologic Disease. Edited by Benson DF, Blumer D. New York: Grune & Stratton; 1975:63–82.
Caselli RJ, Jack CR, Petersen RC, et al.: Asymmetric cortical degenerative syndromes: clinical and radiologic correlations. Neurology 1992, 42:1462–1468.
Duara R, Grady C, Haxby J, et al.: Positron emission tomography in Alzheimer’s disease. Neurology 1986, 36:879–887.
Powers WJ, Perlmutter JS, Videen TO, et al.: Blinded clinical evaluation of positron emission tomography for diagnosis of probable Alzheimer’s disease. Neurology 1992, 42:765–770.
McKhann G, Drachman D, Folstein M, et al.: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984, 34:939–944.
Levine DN, Lee JM, Fisher CM: The visual variant of Alzheimer’s disease. Neurology 1993, 43:305–313.
Victoroff J, Webster R, Benson F, et al.: Posterior cortical atrophy: neuropathologic correlations. Arch Neurol 1994, 51:269–274.
Joaquim CL, Morris JH, Selkoe DJ: Clinically diagnosed Alzheimer’s disease: autopsy results in 150 cases. Ann Neurol 1988, 24:50–56.
Wade JPH, Mirsen TR, Hachinski VC, et al.: The clinical diagnosis of Alzheimer’s disease. Arch Neurol 1987, 44:24–29.
Molsa PK, Paljarvi L, Rinne JO, et al.: Validity of clinical diagnosis in dementia: a prospective clinicopathological study. J Neurol Neurosurg Psychiatr 1985, 48:1085–1090.
Klatka LA, Schiffer RB, Powers JM, Kazee AM: Incorrect diagnosis of Alzheimer’s disease: a clinicopathologic study. Arch Neurol 1996, 53:35–42.
Dickson DW, Davies P, Bevona C, et al.: Hippocampal sclerosis: a common pathological feature of dementia in very old (over 80 years of age) humans. Acta Neuropathol 1994, 88:212–221.
Ala TA, Beh GO, Frey II WH: Pure hippocampal sclerosis. Neurology 2000, 54:843–848.
Katzman R, Kawas C: The epidemiology of dementia and Alzheimer disease. In Alzheimer Disease. Edited by Terry RD, Katzman R, Bick KL. New York: Raven Press; 1994:105–122.
Jorm AF, Korten E, Henderson AS: The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987, 76:465–479.
van Duijn CM, Stijnen T, Hofman A: Risk factors for Alzheimer’s disease: overview of the EURODEM collaborative re-analysis of case-control studies. Int J Epidemiol 1991, 20:S4–S12.
Goate A, Chartier-Harlin MC, Mullan M, et al.: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 1991, 349:704–706.
Levy-Lahad E, Wasco W, Poorkaj P, et al.: Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science 1995, 269:973–977.
Alzheimer’s Disease Collaborative Group: The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Nat Genet 1995, 11:219–222.
Cummings JL, Vinters HV, Cole GM, Khachaturian ZS: Alzheimer’s disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 1998, 51(1 Suppl 1):S2–17.
Strittmatter WJ, Roses AD: Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci U S A 1995, 92:4725–4727.
Myers RH, Schaefer EJ, Wilson PWF, et al.: Apolipoprotein E4 association with dementia in a population-based study: the Framingham Study. Neurology 1996, 46:673–677.
Welsh-Bohmer KA, Gearing M, Saunders AM, et al.: Apolipoprotein E genotypes in a neuropathological series from the Consortium to Establish a Registry for Alzheimer’s Disease. Ann Neurol 1997, 42:319–325.
Breitner JCS: The end of Alzheimer’s disease? Int J Geriatr Psychiatry 1999, 14:577–586.
Hyman BT, Gomez-Isla T, Briggs M, et al.: Apolipoprotein E and cognitive change in an elderly population. Ann Neurol 1996, 40:55–66.
Mayeux R, Saunders AM, Shea S, et al.: Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. N Engl J Med 1998, 338:506–511.
Strittmatter WJ, Saunders AM, Schmechel D, et al.: Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993, 90:1977–1981.
Pickering-Brown SM, Mann DMA, Bourke JP, et al.: Apolipoprotein E4 and Alzheimer’s disease pathology in Lewy body disease and in other beta-amyloid-forming diseases. Lancet 1994, 343:1155.
Ellis RJ, Olichney JM, Thal LJ, et al.: Cerebral amyloid angiopathy in the brains of patients with Alzheimer’s disease: the CERAD experience, part XV. Neurology 1996, 46:1592–1596.
Storey E, Cappai R: The amyloid precursor protein of Alzheimer’s disease and the Ab peptide. Neuropathol Appl Neurobiol 1999, 25:81–97.
Selkoe DJ: Alzheimer’s disease: a central role for amyloid. J Neuropathol Exp Neurol 1994, 53:438–447.
Selkoe DJ: The pathophysiology of Alzheimer’s disease. In Early Diagnosis of Alzheimer’s Disease. Edited by Scinto LFM, Daffner KR. Totowa, NJ: Humana Press; 2000:83–104.
Nicoll JA, Wilkinson D, Holmes C, et al.: Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003, 9:448–452.
Klunk WE, Engler H, Nordberg A, et al.: Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 2004, 55:306–319.
Arnold SE, Hyman BT, Flory J, et al.: The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer’s disease. Cereb Cortex 1991, 1:103–116.
Braak H, Braak E: Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991, 82:239–259.
Hyman BT, Arriagada PV, McKee AC, et al.: The earliest symptoms of Alzheimer disease: anatomic correlates. Soc Neurosci Abstr 1991, 15:352.
Hof PR, Bierer LM, Perl DP, et al.: Evidence for early vulnerability of the medial and inferior aspects of the temporal lobe in an 82-yearold patient with preclinical signs of dementia. Arch Neurol 1992, 49:946–953.
Goulding JMR, Signorini DF, Chatterjee S, et al.: Inverse relation between Braak stage and cerebrovascular pathology in Alzheimer predominant dementia. J Neurol Neurosurg Psychiatry 1999, 67:654–657.
Davies P, Maloney AJF: Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 1976, ii:1403.
Bartus RT, Dean RLI, Beer B, Lippa AS: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217:408–414.
Coyle JT, Price DL, DeLong MR: Alzheimer’s disease: a disorder of cortical cholinergic innervation. Science 1983, 219:1184–1190.
Selden NR, Gitelman DR, Salamon-Murayama N, et al.: Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 1998, 121(Pt 12):2249–2257.
Hyman BT, Van Hoesen G, Damasio AR, Barnes CL: Alzheimer’s disease: cell-specific pathology isolates the hippocampal formation. Science 1984, 225:1168–1170.
Petersen RC, Parisi JE, Dickson DW, et al.: Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 2006, 63:665–672.
Jicha GA, Petersen RC, Knopman DS, et al.: Argyrophilic grain disease in demented subjects presenting initially with amnestic mild cognitive impairment. J Neuropathol Exp Neurol 2006, 65:602–609.
Hof PR, Bouras C, Constantinidis J, Morrison JH: Selective disconnection of specific visual association pathways in cases of Alzheimer’s disease presenting with Balint’s syndrome. J Neuropathol Exp Neurol 1990, 40:168–184.
Consensus report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease.” The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Neurobiol Aging 1998, 19:109–116.
Galasko D, Clark C, Chang L, et al.: Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer’s disease. Neurology 1997, 48:632–635.
Kahle PJ, Jakowec M, Teipel SJ, et al.: Combined assessment of tau and neuronal thread protein in Alzheimer’s disease CSF. Neurology 2000, 54:1498–1504.
Roman GC, Tatemichi TK, Erkinjuntti T, et al.: Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993, 43:250–260.
Tatemichi TK: How acute brain failure becomes chronic: a view of the mechanisms of dementia related to stroke. Neurology 1990, 40:1652–1659.
Tatemichi TK, Desmond DW, Paik M, et al.: Clinical determinants of dementia related to stroke. Ann Neurol 1993, 33:568–575.
Erkinjuntti T, Hachinski VC: Rethinking vascular dementia. Cerebrovasc Dis 1993, 3:3–23.
Chui HC, Victoroff JI, Margolin D, et al.: Criteria for the diagnosis of ischemic vascular dementia proposed by the state of California Alzheimer’s disease diagnostic and treatment centers. Neurology 1992, 42:473–480.
Rockwood K, Parhad I, Hachinski V, et al.: Diagnosis of vascular dementia: Consortium of Canadian Centres for Clinical Cognitive Research consensus statement. Can J Neurol Sci 1994, 21:358–364.
Verhey FRJ, Lodder J, Rozendaal N, Jolles J: Comparison of seven sets of criteria used for the diagnosis of vascular dementia. Neuroepidemiology 1996, 15:166–172.
Erkinjuntti T, Haltia M, Palo J, et al.: Accuracy of the clinical diagnosis of vascular dementia: a prospective clinical and post-mortem neuropathological study. J Neurol Neurosurg Psychiatr 1988, 51:1037–1044.
Gold G, Giannakpoulos P, Montes-Paixao C, et al.: Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia. Neurology 1997, 49:690–694.
Tatemichi TK, Desmond DW, Mayeux R, et al.: Dementia after stroke: baseline frequency, risks, and clinical features in a hospitalized cohort. Neurology 1992, 42:1185–1193.
Hebert R, Brayne C: Epidemiology of vascular dementia. Neuroepidemiology 1995, 14:240–257.
Hershey LA, Modic MT, Jaffe DF, Greenough PG: Natural history of the vascular dementias: a prospective study of seven cases. Can J Neurol Sci 1986, 13:559–565.
Snowdon DA, Greiner LH, Mortimer JA, et al.: Brain infarction and the clinical expression of Alzheimer disease: the Nun study. JAMA 1997, 277:813–817.
Esiri MM, Nagy Z, Smith MZ, et al.: Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer’s disease. Lancet 1999, 354:919–920.
Lie JT: Primary (granulomatous) angiitis of the central nervous system: a clinicopathologic analysis of 15 new cases and a review of the literature. Hum Pathol 1992, 23:164–171.
Caplan LR: Binswanger’s disease: revisited. Neurology 1995, 45:626–633.
Fisher CM: Binswanger’s encephalopathy: a review. J Neurol 1989, 236:65–79.
Greenberg SM, Vonsattel JPG, Stakes JW, et al.: The clinical spectrum of cerebral amyloid angiopathy: presentations without lobar hemorrhage. Neurology 1993, 43:2073–2079.
Greenberg SM, Finklestein SP, Schaefer PW: Petechial hemorrhages accompanying lobar hemorrhage: detection by gradient-echo MRI. Neurology 1996, 46:1751–1754.
Hutchinson, M, O’Riordan J, Javed M, et al.: Familial hemiplegic migraine and autosomal dominant arteriopathy with leukoencephalopathy (CADASIL). Ann Neurol 1995, 38:817–824.
Dichgans M, Mayer M, Uttner I, et al.: The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol 1998, 44:731–739.
The Lund and Manchester Groups: Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994, 57:416–418.
Neary D, Snowden JS, Gustafson L, et al.: Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998, 51:1546–1554.
Brun A: Frontal lobe degeneration of non-Alzheimer type. I. Neuropathology. Arch Gerontol Geriatr 1987, 6:193–208.
Neary D, Snowden JS, Mann DMA, et al.: Frontal lobe dementia and motor neuron disease. J Neurol Neurosurg Psychiatry 1990, 53:23–32.
Chow TW, Miller BL, Hayashi VN, Geschwind DH: Inheritance of frontotemporal dementia. Arch Neurol 1999, 56:817–822.
Forman MS, Farmer J, Johnson JK, et al.: Frontotemporal dementia: clinicopathological correlations. Ann Neurol 2006, 59:952–962.
Tissot R, Constantinidis J, Richard J: Pick’s disease. In Handbook of Clinical Neurology, vol 46. Edited by Frederiks JAM. Amsterdam: Elsevier Science Publishers; 1985:233–246.
Turner RS, Kenyon LC, Trojanowski JQ, et al.: Clinical, neuroimaging, and pathologic features of progressive nonfluent aphasia. Ann Neurol 1996, 39:166–173.
Knopman DS, Mastri AR, Frey II WH, et al.: Dementia lacking distinctive histologic features: a common non-Alzheimer degenerative dementia. Neurology 1990, 40:251–256.
Knopman DS: Overview of dementia lacking distinctive histology: pathological designation of a progressive dementia. Dementia 1993, 4:132–136.
Giannakopoulos P, Hof PR, Bouras C: Dementia lacking distinctive histopathology: clinicopathological evaluation of 32 cases. Acta Neuropathol 1995, 89:346–355.
Boeve BF, Baker M, Dickson DW, et al.: Frontotemporal dementia and parkinsonism associated with the IVS1+1G→A mutation in progranulin: a clinicopathologic study. Brain 2006, 129(Pt 11):3103–3114.
Foster NL, Wilhelmsen K, Sima AAF, et al.: Frontotemporal dementia and Parkinsonism linked to chromosome 17: a consensus conference. Ann Neurol 1997, 41:706–715.
Spillantini, MG, Bird TD, Ghetti B: Frontotemporal dementia and parkinsonism linked to chromosome 17: a new group of tauopathies. Brain Pathol 1998, 8:387–402.
Spillantini MG, Goedert M: Tau protein pathology in neurodegenerative diseases. Trends Neurosci 1998, 21:428–433.
Bennet P, Bonifati V, Bonuccelli U, et al.: Direct genetic evidence for involvement of tau in progressive supranuclear palsy. European Study Group on Atypical Parkinsonism Consortium. Neurology 1998, 51:982–985.
Gearing M, Olson DA, Watts RL, Mirra SS: Progressive supranuclear palsy: neuropathologic and clinical heterogeneity. Neurology 1994, 44:1015–1024.
Mesulam MM: Slowly progressive aphasia without generalized dementia. Ann Neurol 1982, 11:592–598.
Snowden JS, Neary D, Mann DMA: Fronto-Temporal Lobar Degeneration: Fronto-Temporal Dementia, Progressive Aphasia, Semantic Dementia. New York: Churchill Livingstone; 1996.
Kertesz A, Hudson L, Mackenzie IRA, Munoz DG: The pathology and nosology of primary progressive aphasia. Neurology 1994, 44:2065–2072.
Graff-Radford NR, Damasio AR, Hyman BT, et al.: Progressive aphasia in a patient with Pick’s disease: a neuropsychological, radiologic, and anatomic study. Neurology 1990, 40:620–626.
Hodges JR, Patterson K, Oxbury S, Funnell E: Semantic dementia: progressive fluent aphasia with temporal lobe atrophy. Brain 1992, 115:1783–1806.
Gibb WRG, Luthert PJ, Marsden CD: Corticobasal degeneration. Brain 1989, 112:1171–1192.
Boeve BF, Maraganore DM, Parisi JE, et al.: Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 1999, 53:795–800.
Grimes DA, Lang AE, Bergeron CB: Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology 1999, 53:1969–1974.
de Vos RA, Jansen EN, Stam FC, Swaab DF: ‘Lewy body disease’: clinicopathological correlations in 18 consecutive cases of Parkinson’s disease with and without dementia. Clin Neurol Neurosurg 1995, 97:13–22.
Hughes AJ, Daniel SE, Blankson S, Lees AJ: A clinicopathologic study of 100 cases of Parkinson’s disease. Arch Neurol 1993, 50:140–148.
Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992, 55:181–184.
Hulette C, Mirra S, Wilkinson W, et al.: The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part IX. A prospective cliniconeuropathologic study of Parkinson’s features in Alzheimer’s disease. Neurology 1996, 45:1991–1995.
Ditter SM, Mirra SS: Neuropathologic and clinical features of Parkinson’s disease in Alzheimer’s disease patients. Neurology 1987, 37:754–760.
Dickson DW, Ruan D, Crystal H, et al.: Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer’s disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology 1991, 41:1402–1409.
Kim H, Gearing M, Mirra SS: Ubiquitin-positive CA2/3 neurites in hippocampus coexist with cortical Lewy bodies. Neurology 1995, 45:1768–1770.
Lippa CF, Johnson R, Smith TW: The medial temporal lobe in dementia with Lewy bodies: a comparative study with Alzheimer’s disease. Ann Neurol 1998, 43:102–106.
Whitwell JL, Weigand SD, Shiung MM, et al.: Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer’s disease. Brain 2007, 130(Pt 3):708–719.
Ferman TJ, Boeve BF: Dementia with Lewy bodies. Neurol Clin 2007, 25:741–760.
McKeith IG, Fairbairn AF, Bothwell RA, et al.: An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type. Neurology 1994, 44:872–877.
McKeith IG, Ballard CG, Perry RH, et al.: Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000, 54:1050–1058.
Verghese J, Crystal HA, Dickson DW, Lipton RB: Validity of clinical criteria for the diagnosis of dementia with Lewy bodies. Neurology 1999, 53:1974–1982.
McKeith IG, Perry EK, Perry RH: Report of the second dementia with Lewy body international workshop. Neurology 1999, 53:902–905.
Boeve BF, Silber MH, Ferman TJ, et al.: REM sleep behavior disorder and degenerative dementia: an association likely reflecting Lewy body disease. Neurology 1998, 51:363–370.
McKeith I, Fairbairn A, Perry R, et al.: Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992, 305:673–678.
Ballard C, Grace J, McKeith I, Holmes C: Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer’s disease. Lancet 1998, 351:1032–1033.
Walker MP, Ayre GA, Cummings JL, et al.: Quantifying fluctuation in dementia with Lewy bodies, Alzheimer’s disease, and vascular dementia. Neurology 2000, 54:1616–1624.
Prusiner SB: The prion diseases. Sci Am 1995, 272:48–57.
Bortone E, Bettoni L, Giorgi C, et al.: Reliability of EEG in the diagnosis of Creutzfeldt-Jakob disease. Electroencephalogr Clin Neurophysiol 1994, 90:323–330.
Steinhoff BJ, Racker S, Herrendorf G, et al.: Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease. Arch Neurol 1996, 53:162–166.
Zerr I, Bodemer M, Gefeller O, et al.: Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol 1998, 43:32–40.
Na DL, Suh CK, Choi SH, et al.: Diffusion-weighted magnetic resonance imaging in probable Creutzfeldt-Jakob disease: a clinical-anatomic correlation. Arch Neurol 1999, 56:951–957.
DeArmond SJ, Prusiner SB: Etiology and pathogenesis of prion diseases. Am J Pathol 1995, 146:785–811.
Parchi P, Giese A, Capellari S, et al.: Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999, 46:224–233.
Mestel R: Putting prions to the test. Science 1996, 273:184–189.
Will RG, Ironside JW, Zeidlee M, et al.: A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996, 347:921–925.
Johnson RT, Gibbs CJ: Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. N Engl J Med 1998, 339:1994–2004.
Gultekin SH, Rosenfeld MR, Voltz R, et al.: Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000, 123:1481–1494.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Current Medicine Group LLC, part of Springer Science+Business Media LLC
About this chapter
Cite this chapter
Grabowski, T.J. (2009). Dementias. In: Rosenberg, R.N. (eds) Atlas of Clinical Neurology. Current Medicine Group. https://doi.org/10.1007/978-1-57340-359-7_6
Download citation
DOI: https://doi.org/10.1007/978-1-57340-359-7_6
Publisher Name: Current Medicine Group
Print ISBN: 978-1-57340-283-5
Online ISBN: 978-1-57340-359-7
eBook Packages: MedicineMedicine (R0)